Twenty-year brain magnetic resonance imaging follow-up study in Systemic Lupus Erythematosus: Factors associated with accrual of damage and central nervous system involvement

Autoimmunity Reviews

Volumn 14, Issue 6, 2015, Pages 510-516

  Piga, Matteo ^a   Peltz, Maria Teresa ^b   Montaldo, Carlo ^c   Perra, Daniela ^a   Sanna, Giovanni ^d,e   Cauli, Alberto ^a   Mathieu, Alessandro ^a  

^a DEPARTMENT OF RADIOLOGY   (Italy)

^b BROTZU HOSPITAL   (Italy)

^c CTO Hospital   (Italy)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Brain; MRI; Neuropsychiatric SLE; SLE; Stroke

Indexed keywords

ANTIMALARIAL AGENT; CORTICOSTEROID;

ADULT; ANXIETY DISORDER; ARTICLE; BRAIN DAMAGE; BRAIN DISEASE; BRAIN ISCHEMIA; BRAIN PARENCHYMAL DEFECT; BRAIN SIZE; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COGNITIVE DEFECT; CORTICOSTEROID THERAPY; DISEASE COURSE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEADACHE; HUMAN; MALE; MENTAL DISEASE; MODIFIED MRI SCORING SYSTEM; MONONEUROPATHY; MOOD DISORDER; MYELITIS; NERVOUS SYSTEM PARAMETERS; NEUROPROTECTION; NEURORADIOLOGIST; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; RISK FACTOR; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSIENT ISCHEMIC ATTACK; WHITE MATTER HYPERINTENSITY; BRAIN; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

BRAIN; CENTRAL NERVOUS SYSTEM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME;

EID: 84933679537     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.01.010     Document Type: Article

References (60)

1. Sciascia S., Bertolaccini M.L., Baldovino S., Roccatello D., Khamashta M.A., Sanna G. Central nervous system involvement in systemic lupus erythematosus: overview on classification criteria. Autoimmun Rev 2013, 12:426-429.
2. Zirkzee E.J., Steup-Beekman G.M., van der Mast R.C., Bollen E.L., van der Wee N.J., Baptist E., et al. Prospective study of clinical phenotypes in neuropsychiatric systemic lupus erythematosus; multidisciplinary approach to diagnosis and therapy. J Rheumatol 2012, 39:2118-2126.
3. Hanly J.G., Urowitz M.B., Sanchez-Guerrero J., Bae S.C., Gordon C., Wallace D.J., et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum 2007, 56:265-273.
4. Hanly J.G., Urowitz M.B., Su L., Sanchez-Guerrero J., Bae S.C., Gordon C., et al. Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum 2008, 59:721-729.
5. Hanly J.G., Urowitz M.B., Su L., Bae S.C., Gordon C., Wallace D.J., et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2010, 69:529-535.
6. Fragoso-Loyo H.E., Sanchez-Guerrero J. Effect of severe neuropsychiatric manifestations on short-term damage in systemic lupus erythematosus. J Rheumatol 2007, 34:76-80.
7. Hanly J.G., Su L., Farewell V., McCurdy G., Fougere L., Thompson K. Prospective study of neuropsychiatric events in systemic lupus erythematosus. J Rheumatol 2009, 36:1449-1459.
8. Al Dhanhani A.M., Gignac M.A., Su J., Fortin P.R. Work disability in systemic lupus erythematosus. Arthritis Rheum 2009, 61:378-385.
9. Cervera R., Khamashta M.A., Font J., Sebastiani G.D., Gil A., Lavilla P., et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period. A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003, 82:299-308.
10. Zardi E.M., Taccone A., Marigliano B., Margiotta D.P., Afeltra A. Neuropsychiatric systemic lupus erythematosus: tools for the diagnosis. Autoimmun Rev 2014, 13:831-839.
11. Toledano P., Sarbu N., Espinosa G., Bargalló N., Cervera R. Neuropsychiatric systemic lupus erythematosus: magnetic resonance imaging findings and correlation with clinical and immunological features. Autoimmun Rev 2013, 12:1166-1170.
12. Sibbitt W.L., Sibbitt R.R., Brooks W.M. Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1999, 42:2026-2038.
13. Sibbitt W.L., Schmidt P.J., Hart B.L., Brooks W.M. Fluid attenuated inversion recovery (FLAIR) imaging in neuropsychiatric systemic lupus erythematosus. J Rheumatol 2003, 30:1983-1989.
14. Appenzeller S., Vasconcelos Faria A., Li L.M., Costallat L.T., Cendes F. Quantitative magnetic resonance imaging analyses and clinical significance of hyperintense white matter lesions in systemic lupus erythematosus patients. Ann Neurol 2008, 64:635-643.
15. Castellino G., Padovan M., Bortoluzzi A., Borrelli M., Feggi L., Caniatti M.L., et al. Single photon emission computed tomography and magnetic resonance imaging evaluation in SLE patients with and without neuropsychiatric involvement. Rheumatology (Oxford) 2008, 47:319-323.
16. Ainiala H., Dastidar P., Loukkola J., Lehtimaki T., Korpela M., Peltola J., et al. Cerebral MRI abnormalities and their association with neuropsychiatric manifestations in SLE: a population-based study. Scand J Rheumatol 2005, 34:376-382.
17. Appenzeller S., Rondina J.M., Li L.M., Costallat L.T., Cendes F. Cerebral and corpus callosum atrophy in systemic lupus erythematosus. Arthritis Rheum 2005, 52:2783-2789.
18. Jung R.E., Segall J.M., Grazioplene R.G., Qualls C., Sibbitt W.L., Roldan C.A. Cortical thickness and subcortical gray matter reductions in neuropsychiatric systemic lupus erythematosus. PLoS One 2010, 5:e9302.
19. Sanna G., Piga M., Terryberry J.W., Peltz M.T., Giagheddu S., Satta L., et al. Central nervous system involvement in systemic lupus erythematosus: cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations. Lupus 2000, 9:573-583.
20. Luyendijk J., Steens S.C., Ouwendijk W.J., Steup-Beekman G.M., Bollen E.L., van der Grond J., et al. Neuropsychiatric systemic lupus erythematosus: lessons learned from magnetic resonance imaging. Arthritis Rheum 2011, 63:722-732.
21. Petri M., Naqibuddin M., Carson K.A., Wallace D.J., Weisman M.H., Holliday S.L., et al. Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus. J Rheumatol 2008, 35:2348-2354.
22. Sarbu N., Alobeidi F., Toledano P., Espinosa G., Giles I., Rahman A., et al. Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. Autoimmun Rev 2015, 14:153-159.
23. Appenzeller S., Bonilha L., Rio P.A., Min Li L., Costallat L.T., Cendes F. Longitudinal analysis of gray and white matter loss in patients with systemic lupus erythematosus. Neuroimage 2007, 34:694-701.
24. Castellino G., Bortoluzzi A., Padovan M., Borrelli M., Feggi L., Govoni M. Repeated brain conventional MRI and SPECT evaluation in systemic lupus erythematosus patients with and without neuropsychiatric involvement: a follow-up study. Lupus 2011, 20:1387-1395.
25. Karassa F.B., Ioannidis J.P., Boki K.A., Touloumi G., Argyropoulou M.I., Strigaris K.A., et al. Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med 2000, 109:628-634.
26. Castellino G., Govoni M., Padovan M., Colamussi P., Borrelli M., Trotta F. Proton magnetic resonance spectroscopy may predict future brain lesions in SLE patients: a functional multi-imaging approach and follow-up. Ann Rheum Dis 2005, 64:1022-1027.
27. Cauli A., Montaldo C., Peltz M.T., Nurchis P., Sanna G., Garau P., et al. Abnormalities of magnetic resonance imaging of the central nervous system in patients with systemic lupus erythematosus correlate with disease severity. Clin Rheumatol 1994, 13:615-618.
28. Govoni M., Bombardieri S., Bortoluzzi A., Caniatti L., Casu C., Conti F., et al. Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology (Oxford) 2012, 51:157-168.
29. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997, 157:2413-2446.
30. World Health Organization Obesity: preventing and managing the global epidemic 1997, WHO, Geneva.
31. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 20:1183-1197.
32. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
33. Wilson W.A., Gharavi A.E., Koike T., Lockshin M.D., Branch D.W., Piette J.C., et al. International consensus statement on preliminary classification criteria for definitive antiphospholipid syndrome. Arthritis Rheum 1999, 42:1309-1311.
34. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61:554-558.
35. Gladman D.D., Goldsmith C.H., Urowitz M.B., Bacon P., Fortin P., Ginzler E., et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison. J Rheumatol 2000, 27:373-376.
36. Piga M., Mathieu A. Managing CNS involvement in systemic lupus erythematosus. Int J Clin Rheumatol 2011, 6:547-567.
37. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999, 42:599-608.
38. Ainiala H., Loukkola J., Peltola J., Korpela M., Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001, 57:496-500.
39. Bortoluzzi A., Scirè C.A., Bombardieri S., Caniatti L.M., Conti F., De Vita S., et al. Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology (Oxford) 2014 Oct 21, [pii: keu384 [Epub ahead of print]]. 10.1093/rheumatology/keu384.
40. Bertsias G.K., Ioannidis J.P., Aringer M., Bollen E., Bombardieri S., Bruce I.N., et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010, 69:2074-2082.
41. Sibbitt W.L., Brooks W.M., Kornfeld M., Hart B.L., Bankhurst A.D., Roldan C.A. Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus. Semin Arthritis Rheum 2010, 40:32-52.
42. Arinuma Y., Yanagida T., Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2008, 58:1130-1135.
43. Sanna G., Bertolaccini M.L., Cuadrado M.J., Khamashta M.A., Hughes G.R. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology (Oxford) 2003, 42:200-213.
44. Mathieu A., Vacca A., Serra A., Cauli A., Piga M., Porru G., et al. Defective cerebral gamma-aminobutyric acid-A receptor density in patients with systemic lupus erythematosus and central nervous system involvement. An observational study. Lupus 2010, 19:918-926.
45. Tsuchiya H., Haga S., Takahashi Y., Kano T., Ishizaka Y., Mimori A. Identification of novel autoantibodies to GABA(B) receptors in patients with neuropsychiatric systemic lupus erythematosus. Rheumatology (Oxford) 2014, 53:1219-1228.
46. Jennekens F.G., Kater L. The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology (Oxford) 2002, 41:605-618.
47. Brooks W.M., Sibbitt W.L., Kornfeld M., Jung R.E., Bankhurst A.D., Roldan C.A. The histopathologic associates of neurometabolite abnormalities in fatal neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2010, 62:2055-2063.
48. Jeltsch-David H., Muller S. Neuropsychiatric systemic lupus erythematosus and cognitive dysfunction: the MRL-lpr mouse strain as a model. Autoimmun Rev 2014, 13:963-973.
49. Stagi S., Rigante D., Lepri G., Bertini F., Matucci-Cerinic M., Falcini F. Evaluation of autoimmune phenomena in patients with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). Autoimmun Rev 2014, 13:1236-1240.
50. Kozora E., West S.G., Kotzin B.L., Julian L., Porter S., Bigler E. Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 1998, 41:41-47.
51. Vernooij M.W., Ikram M.A., Tanghe H.L., Vincent A.J., Hofman A., Krestin G.P., et al. Incidental findings on brain MRI in the general population. N Engl J Med 2007, 357:1821-1828.
52. Roldan C.A., Gelgand E.A., Qualls C.R., Sibbitt W.L. Valvular heart disease by transthoracic echocardiography is associated with focal brain injury and central neuropsychiatric systemic lupus erythematosus. Cardiology 2007, 108:331-337.
53. de Leeuw F.E., de Groot J.C., Oudkerk M., Witteman J.C., Hofman A., van Gijn J., et al. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain 2002, 125:765-772.
54. Appenzeller S., Li L.M., Costallat L.T., Cendes F. Neurometabolic changes in normal white matter may predict appearance of hyperintense lesions in systemic lupus erythematosus. Lupus 2007, 16:963-971.
55. Futatsuya K., Kakeda S., Kaichi Y., Moriya J., Ohnari N., Saito K., et al. Systemic lupus erythematosus: prediction by MRI of the subsequent development of brain lesions. Acad Radiol 2014, 21:617-623.
56. Vermeer S.E., Hollander M., van Dijk E.J., Hofman A., Koudstaal P.J., Breteler M.M. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003, 34:1126-1129.
57. Bruce I.N., O'Keeffe A.G., Farewell V., Hanly J.G., Manzi S., Su L., et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis 2014, [pii: annrheumdis-2013-205171, Epub ahead of print]. 10.1136/annrheumdis-2013-205171.
58. Bruce I.N. 'Not only. . .but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 2005, 44:1492-1502.
59. Chinn R.J., Wilkinson I.D., Hall-Craggs M.A., Paley M.N., Shortall E., Carter S., et al. Magnetic resonance imaging of the brain and cerebral proton spectroscopy in patients with systemic lupus erythematosus. Arthritis Rheum 1997, 40:36-46.
60. Zanardi V.A., Magna L.A., Costallat L.T. Cerebral atrophy related to corticotherapy in systemic lupus erythematosus (SLE). Clin Rheumatol 2001, 20:245-250.